ProCE Banner Activity

Evolution of TROP2-Targeted ADCs in Solid Tumors


Download this slideset from a live symposium at AACR 2023 to review expert perspectives on structural features and current clinical data with TROP2-targeted antibody-drug conjugates, with a focus on use of these agents in breast and lung cancers.

Released: April 20, 2023



Rebecca S. Heist

Rebecca S. Heist, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Funda Meric-Bernstam

Funda Meric-Bernstam, MD

Chair, Department of Investigational Cancer Therapeutics
Medical Director, Institute of Personalized Cancer Therapy
Nellie B. Connally Chair in Breast Cancer
The University of Texas MD Anderson Cancer Center
Houston, Texas

Paolo Tarantino

Paolo Tarantino, MD

Advanced Research Fellow
Harvard Medical School
Department of Breast Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants: AstraZeneca and Daiichi Sankyo, Inc.


Daiichi Sankyo, Inc.